ERBB2 and heart failure: Although these oral heart failure therapies used specifically for primary prevention were not associated with a statistically significant reduction in the risk of HER2-directed antibody-associated cardiotoxicity as defined by each study, the use of these agents possibly prevents deterioration in left ventricular function as a continuous measure, and were associated with a significant reduction in HER2 therapy interruptions.